Company Overview
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.13.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +184.07% |
| 6 Months: | -42.37% |
| 3 Months: | +137.78% |
| 1 Month: | +12.63% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)62.93 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 55.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PEPG PepGen Inc. PHARMA | 3.21 | -3.21 | $222.32M | 0.00% | -58.05% | -75.45% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 31.32M | 23.93M | 18.65M | 19.70M | 18.94M | - |
| Operating Income | -6.63M | -5.19M | -8.08M | -13.89M | -17.64M | -19.55M | -18.03M | -21.14M | -24.78M | -19.80M | -30.43M | -23.17M | -31.32M | -23.93M | -18.65M | -19.70M | -18.94M | -18.94M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -30.00M | -22.66M | -17.38M | -18.43M | -17.69M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -30.20M | -23.09M | -18.03M | -18.29M | -17.75M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 49.00K | 15.00K | - |
| Net Income | -6.64M | -5.39M | -8.11M | -18.25M | -17.32M | -18.61M | -16.32M | -19.52M | -23.29M | -18.02M | -28.34M | -21.38M | -30.20M | -23.09M | -18.03M | -18.34M | -17.76M | -17.81M |
| Diluted EPS | - | -6.03 | -9.07 | -18.94 | -1.23 | -0.79 | -0.69 | -0.82 | -0.98 | -0.63 | -0.87 | -0.66 | -0.92 | -0.70 | -0.52 | -0.27 | -0.26 | -0.26 |
| R&D Expense | 5.53M | 3.22M | 5.71M | 10.71M | 14.24M | 15.96M | 14.36M | 16.93M | 20.54M | 14.73M | 25.06M | 17.72M | 25.38M | 18.39M | 13.42M | - | 13.00M | 12.52M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 68.30M | 84.77M | 97.74M | 93.61M |
| Operating Income | - | -68.30M | -84.77M | -97.74M | -93.61M |
| EBITDA | - | -67.81M | -83.92M | -92.49M | -88.47M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -65.40M | -78.55M | -90.60M | -89.61M |
| Tax Provision | - | 3.71M | 73.00K | -617.00K | 49.00K |
| Net Income | - | -69.10M | -78.63M | -89.98M | -89.66M |
| Diluted EPS | - | -2.91 | -3.30 | -2.85 | -2.12 |
| R&D Expense | 19.00M | 54.08M | 68.13M | 76.48M | 71.04M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 217.44M | 143.05M | 150.88M | 173.91M |
| Current Assets | - | - | 186.08M | 112.68M | 123.76M | 150.96M |
| Cash & Equivalents | - | - | 181.75M | 80.77M | 49.42M | 60.51M |
| Inventory | - | - | - | - | - | - |
| Receivables | - | 4.74M | 58.00K | - | - | - |
| Total Liabilities | - | - | 37.81M | 34.63M | 32.26M | 26.46M |
| Current Liabilities | - | - | 18.83M | 17.53M | 16.70M | 12.65M |
| Long Term Debt | - | - | - | - | - | - |
| Total Debt | - | - | 24.53M | 20.10M | 18.66M | 17.00M |
| Total Equity | -6.36M | - | 179.63M | 108.42M | 118.62M | 147.44M |
| Shares Outstanding | - | - | 23.71M | 23.82M | 32.62M | 68.87M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -59.27M | -69.00M | -82.37M | -81.64M |
| Investing Cash Flow | - | -3.75M | -32.00M | -37.67M | -15.23M |
| Financing Cash Flow | - | 112.19M | -189.00K | 88.75M | 107.98M |
| Capital Expenditure | - | -3.75M | -2.60M | -497.00K | -264.00K |
| Free Cash Flow | - | -63.02M | -71.60M | -82.87M | -81.90M |
| Net Change in Cash | - | 49.17M | -101.19M | -31.29M | 11.11M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -38.5% | -72.5% | -75.9% | -60.8% |
| ROCE % | - | -34.4% | -67.5% | -72.8% | -58.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 28.97% | 20.06M | $57.18M |
| 2 | Commodore Capital Lp | 6.46% | 4.47M | $12.75M |
| 3 | Viking Global Investors, L.P. | 5.03% | 3.48M | $9.92M |
| 4 | Laurion Capital Management, LP | 3.97% | 2.75M | $7.84M |
| 5 | Adar1 Capital Management, LLC | 3.74% | 2.59M | $7.38M |
| 6 | Vivo Capital, LLC | 3.36% | 2.33M | $6.63M |
| 7 | Vanguard Capital Management LLC | 2.80% | 1.94M | $5.52M |
| 8 | Millennium Management Llc | 2.58% | 1.79M | $5.09M |
| 9 | Renaissance Technologies, LLC | 2.19% | 1.52M | $4.33M |
| 10 | Blackrock Inc. | 1.88% | 1.30M | $3.72M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PEPG
$PEPG stock is up 14% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQZjdEbklVNXJaMmJSakh6bEQ4bGJpNzNLUnhsazJsOEFzYk9lcWczenZBWXRPeEpPby1nUmh4RTRDZ0xjM19WNmdxak53SFE1T3RydTZOSmtNMTN6RHhyM2gyNlRhT013bzFLcU9HamwyQlp5ck5wQ2RiTGh6NUN4RkJLSHVBV1VDN1ZfRF…
Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPT2c3djRxN1oyeW85V0hCN2JJS0h4UW9pd3ZSa3AzS2xyUG04SkQ2M2FHTktuVVVlREN6Z1BUMXJRN0lrWmVtQW5LOTNWVzZWY1FzU2lXLU00SUl2a25nbjRMOXhib2lYSEc0ZmJpZFVrVmt5QkpnQ0JxWHdvdkI1YkoxZWhpMHhmeXdHbG…
PEPG Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE04cTJma0paYUY5Wk5qWEpfVXR6R1ltQWUtVHFKUzVCYkNQSkktM3ZjOTc0cnllWjI0V1h2UjBpaGtWZjFPZUdldDNGLXVNTzV0YklWME81MFRpQWxTTjZaS2g5ejRvY05PdjlCZF9DQlVSelRtNTdfYnRB?oc=5" target="_blank">PEP…
PEPG - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE45R2ZCV0VlTFpZdU5lYzNKN1hsUWhTdFV4NUFraVNPNEZCbEtVc294NzZIbUxzNlNKZkNxTUNDTi1WVHZlc2c?oc=5" target="_blank">PEPG</a> <font color="#6f6f6f">Finviz</font>…
PepGen Inc (PEPG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5HSUVqNExHb281Rld3QktScDdZTXYxRFUtS3RyT0xwWVZZU3B2Ni1qYV9ZRDMzeEtCQ2FWdWZQcFdRcXFITUpCQlJxVlZ5VndfWUdMVHBVbEd6eVp1R09xcTJzZm1aajg?oc=5" target="_blank">PepGen Inc (PEPG) Technical …
PepGen posts trial data for muscle disorder drug (PEPG:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxQbzNUVFBsMk9odF9DWUpQTi0zUDNqNnFTa0FuZXNGdXBVUGhZVTZLX014NDFBWEJaRkJQY1hmSldFZWVGUkVQei02dGp6ajZJV2d2Q21hR0MzenlmWTFkWjI2WXh5Z25IWXp4anZmZW9nQmJTNHFsM3Vxd190R2dqOHJpaTkzbVQySEE?oc…
PEPG — Frequently Asked Questions
What is the current share price of PepGen Inc. (PEPG)?
As of 2026-09-19 21:16 PDT, PepGen Inc. (PEPG) trades at $3.21 on NasdaqGS. Its 52-week range is $1.13 to $7.17.
What is the market capitalisation of PEPG?
PepGen Inc. (PEPG) has a market capitalisation of $222.32M on NasdaqGS.
What is the P/E ratio of PEPG?
PEPG trades at a trailing price-to-earnings (P/E) ratio of -3.21. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.65.
What is the return on equity (ROE) of PEPG?
PEPG has a return on equity (ROE) of -75.45%. Its return on capital employed (ROCE) is -58.05%.
Is PEPG a good stock to buy?
This page provides a data-driven analysis of PepGen Inc. (PEPG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.